Top 5 Dividend Companies To Watch For 2015

Top 5 Dividend Companies To Watch For 2015: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; p! rofessional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in N e w Brunswick, New Jersey.

Advisors' Opinion:

• [By TaniaC]

  It will compete with a similar drug from Johnson & Johnson (JNJ) called Invokana, as well as diabetes medicines from other classes.

  Details of the Drug

• [By John Udovich]

  Different Biotech Strategies Being Pursued in Europe. In the wake of the controverisial Pfizer Inc (NYSE: PFE) pursuit of AstraZeneca plc (NYSE: AZN), FierceBiotech has a detailed article about the different biotech strategies they along with Johnson & Johnson (NYSE: JNJ) and Bayer AG (OTCMKTS: BAYRY) are pursuing in Europe. Specifically, AstraZeneca is setting aside £5 million ($8.4 million) to fund startups at the Alderley Edge site it is vacating as part of its relocation to Cambridge; Johnson & Johnson has an office in Britain that has inked 16 deals with European biotechs and academic centers last year; and Bayer is inviting biotechs into a new incubator with three startups housed so far.

• [By Ben Levisohn]

  Nevertheless, while we believe that the rejection vote is a setback to Valeant, we remain confident that Valeant will either ultimately succeed in its bid to acquire Allergan near-term or seek to consummate another transaction elsewhere. We note that thus far it does not appear that Allergan has much strategic wiggle room, having already been rebuffed by potential white knights such as Sanofi S.A. (SNY) and Johnson & Johnson (JNJ) and with little chance, in our view, of making a meaningful acquisition of its own, such as the purchase of Shire (SHPG).

• [By Holly LaFon]

  Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor's shares, when redee! med, may ! be worth more or less than original cost. As stated in the current prospectus, the Fund's Investor Class Share's annual operating expense ratio (gross) is 1.28%. The Fund's adviser has contractually agreed to waive a portion of its fee and/or reimburse Fund expenses to limit total annual operating expenses at 1.25%, which is in effect until October 31, 2015. Other share classes may vary. The Fund charges a 2.0% redemption fee on shares redeemed within six months of purchase. For the most recent month-end performance, please call (877)328-9437 or visit the Advisor's website at www.auxierasset.com. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future.Spring 2014 Market CommentaryAuxier Focus Fund's Investor Class returned a modest 0.25% for the quarter ended March 31, while Standard and Poor's 500 Stock Index (S&P) rose 1.81%. The Fund ended the quarter with 70% in U.S. stocks, 16% foreign stocks, 1.7 % bonds and 12.3% cash. Since inception in 1999, the Fund's equity exposure has averaged 72%. Our stockholdings in the healthcare industry generally gained for the quarter. But many of our multinational and foreign stocks were hurt by the threat of currency repercussions from geopolitical events in Russia and Ukraine. The foreign portion of the Fund is easily the most undervalued. Longer term, we see a very favorable risk/reward potential with our UK and European holdings. Some emerging market companies we follow are the cheapest in over twenty years. In allocating capital, we much prefer the gloom of down to flat markets and the corrective process that tempers exuberance. We re member that one of th

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-dividend-companies-to-watch-for-2015.html